MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Cancer of Breast
Interventions: BIOLOGICAL: MCS110|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel|PROCEDURE: Bone marrow aspirate|PROCEDURE: Peripheral blood samples|PROCEDURE: Tumor tissue
Sponsor: Washington University School of Medicine
Collaborators: Novartis Pharmaceuticals